ATLANTA, GA – – (June 28, 2018) – – Holzer & Holzer, LLC is investigating whether Arsanis, Inc. (“Arsanis” or the “Company”) (NASDAQ: ASNS) complied with the federal securities laws. On June 28, 2018, Arsanis announced the discontinuation of its Phase 2 clinical trial of ASN100, a preventive drug for mechanically ventilated patients with a high risk of contracting pneumonia. Arsanis disclosed that an analysis completed by an independent drug review committee found that continuing the trial was “futile” because the target primary end-point likely would not be met upon completion. The price of Arsanis stock fell significantly following the report. If you purchased Arsanis common stock and suffered a loss on that investment, you are encouraged to contact Corey D. Holzer Esq. at firstname.lastname@example.org or Alexandria P. Rankin, Esq. at email@example.com, or call the firm by toll-free telephone at (888) 508-6832.